Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exubera launch

Executive Summary

Pfizer's launch of the inhaled insulin Exubera is slated for June, Human Health President Karen Katen said during an investor meeting Feb. 10. The company had previously said the timeline for launch was mid-year due to supply chain issues, the need for physician education and reimbursement discussions (1"The Pink Sheet" Feb. 13, 2006, p. 23). Katen noted that Pfizer has not yet announced Exubera's pricing but stated "we will possibly announce it" prior to the June lunch. Exubera was approved Jan. 27 for the treatment of adults with type 1 and type 2 diabetes...

You may also be interested in...



Exubera Education, Complicated Manufacturing Impacting Launch Timeline

Pfizer's mid-year launch timeline for its inhaled insulin therapy Exubera is influenced by the need to educate physicians, complex supply chain issues and reimbursement discussions, Pfizer co-development partner Nektar suggested

Finance Watch: Revolution Medicines Continues 2020’s Post-IPO Trend

Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.

New Real-World Data Show Benefits Of Abbott's FreeStyle Libre Technology

New real-world data, presented at a recent diabetes conference in Madrid, showed that Abbott's FreeStyle Libre system provided several clinical benefits for patients with diabetes.

UsernamePublicRestriction

Register

PS046883

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel